Physician profile
Daniel J Ebenezer
NPI 1508838541
$8,387.84
in general payments reported to CMS, 2019-2025
29 companies · $30.34 in 2025
The $30.34 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,042 · 2020: $1,491 · 2021: $1,656 · 2022: $1,647 · 2023: $1,366 · 2024: $155 · 2025: $30.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,271.03 | 2019-2023 | Xarelto |
| Amgen INC. | $999.32 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $907.20 | 2019-2024 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $768.12 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $655.66 | 2019-2024 | |
| Pfizer INC. | $572.92 | 2019-2024 | |
| Amarin Pharma, INC. | $569.93 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $509.89 | 2019-2023 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $379.81 | 2021-2023 | Verquvo |
| Medtronic, INC. | $181.46 | 2023 | Harmony |
| Esperion Therapeutics, INC. | $178.37 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.27 | 2019-2024 | Jardiance |
| Philips North America LLC | $140.27 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $134.06 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.98 | 2019-2023 | Lifevest |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $123.50 | 2019 | |
| Edwards Lifesciences Corporation | $119.79 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $100.29 | 2019-2021 | |
| Elutia, INC. | $96.51 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.93 | 2021-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $65.73 | 2021-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $63.54 | 2023-2024 | Onpattro |
| Biosense Webster, INC. | $46.15 | 2023-2025 | Carto 3 |
| Heartflow, INC. | $42.98 | 2019-2021 | |
| Vifor Pharma, INC. | $23.33 | 2019 | |
| Medtronic Vascular, INC. | $19.00 | 2019 | |
| Boston Scientific Corporation | $18.21 | 2021 | |
| Kestra Medical Technology Services, INC. | $14.45 | 2023 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $14.14 | 2023 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ebenezer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.